查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1599359

外陰痛治療市場：按類型、適應症、提供者分類 - 全球預測 2025-2030

Vulvodynia Treatment Market by Type (Biofeedback & Physical Therapy, Intralesional Injections, Oral Treatment), Indication (Generalized Vulvodynia, Localized Vulvodynia), Providers - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

外陰疼痛治療市場2023年估值為555.3億美元，預計到2024年將達到608.2億美元，複合年成長率為9.62%，預計到2030年將達到1056.7億美元。

外陰痛是一種影響外陰的慢性疼痛狀況，有多種治療選擇，從藥物、物理治療到手術介入。有效外陰痛治療的需求源自於外陰痛對生活品質的嚴重影響，凸顯了對創新和全面解決方案的需求。外陰痛治療的應用主要針對婦科診所、醫院和專業疼痛管理中心，隨著遠端醫療和家庭治療套件的進步擴大了居家醫療的最終用途。外陰痛治療市場的成長主要受到患者和醫療保健專業人員意識的提高、非侵入性治療技術的進步以及政府支持政策的影響。藥品電子商務的興起也為分銷和患者外展提供了新的途徑。最新的潛在治療機會源於個人化醫療的不斷成長的趨勢，該趨勢側重於為患者量身定做治療的基因組方法，以及結合了物理、心理和替代療法的整體治療。然而，這個市場面臨阻礙患者轉診和獲得治療的重大限制，包括診斷不足、社會恥辱和全科醫生知識有限。價格敏感性和某些治療方法缺乏保險覆蓋也構成了市場滲透挑戰。預計成長的創新和研發領域包括非鴉片類止痛藥的開發、雷射療法的進步以及數位健康工具，例如用於患者管理和教育的應用程式。這些創新可以提高患者的依從性和治療結果。市場動態是動態的，患者對侵入性較小、更有效的治療的需求也在不斷變化。希望進入或擴展該市場的公司應專注於與醫療保健提供者合作、投資於患者教育計劃以及培育社區支持網路，以減少社會障礙並改善獲得護理的機會。

主要市場統計
基準年[2023] 555.3億美元
預測年份 [2024] 608.2億美元
預測年份 [2030] 1056.7億美元
複合年成長率（%） 9.62%

市場動態：快速發展的外陰痛治療市場的關鍵市場洞察

供需的動態交互作用正在改變外陰痛治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 提高臨床醫生，特別是婦科醫生對外陰百日菊診斷的認知
    • 醫療保健設施和診斷服務的發展
    • 增加研發活動
  • 市場限制因素
    • 原因未知，診斷選擇有限。
  • 市場機會
    • 醫生提供的外陰自我護理和治療
    • 仿單標示外療法的長期可用性
  • 市場挑戰
    • 醫療保健提供者對外陰痛缺乏了解

波特的五力：駕馭外陰痛治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外陰痛治療市場的外在影響

外部宏觀環境因素在塑造外陰痛治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解外陰痛治療市場的競爭狀況

對外陰痛治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣外陰痛治療市場供應商的績效評估

FPNV 定位矩陣是評估外陰痛治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製外陰痛治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，外陰痛治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 臨床醫生，尤其是婦科醫師對外陰痛診斷的了解不斷增加
      • 醫療保健設施和診斷服務的發展
      • 增加研發活動
    • 抑制因素
      • 原因未知，診斷選項有限
    • 機會
      • 醫生提供外陰痛的自我護理和治療
      • 長期供應仿單標示外藥品
    • 任務
      • 醫療保健專業人員對外陰痛的了解有限
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章外陰疼痛治療市場：依類型

  • 生物回饋療法和物理治療
  • 病灶內注射
  • 口服治療
  • 手術治療
  • 局部治療

第7章外陰痛治療市場（依適應症）

  • 全身性外陰痛
  • 局部外陰痛

第8章外陰痛治療市場（依提供者分類）

  • 醫院和護理提供者
  • 製藥和生物技術公司
  • 研發中心

第9章 北美及南美外陰痛治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區外陰痛治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的外陰痛治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amneal Pharmaceuticals, Inc.
  • Cipla Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Inc.
  • GTO Pharmaceutical, LLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Taro Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories, LLC
  • VuVatech LLC
  • Zydus Lifesciences Limited
Product Code: MRR-433BAD49EE73

The Vulvodynia Treatment Market was valued at USD 55.53 billion in 2023, expected to reach USD 60.82 billion in 2024, and is projected to grow at a CAGR of 9.62%, to USD 105.67 billion by 2030.

Vulvodynia is a chronic pain condition affecting the vulva, with numerous treatment options ranging from medications and physical therapy to surgical interventions. The necessity for effective vulvodynia treatments stems from its profound impact on the quality of life, emphasizing the need for innovative and comprehensive solutions. The applications of vulvodynia treatments are primarily targeted towards gynecological clinics, hospitals, and specialty pain management centers, with increasing end-use scope in home care settings owing to advancements in telemedicine and home-treatment kits. Market growth for vulvodynia treatments is primarily influenced by increasing awareness among patients and healthcare professionals, technological advancements in non-invasive treatments, and supportive government policies. The rise of e-commerce in pharmaceuticals also provides new avenues for distribution and patient outreach. Latest potential opportunities lie in personalized medicine, focusing on genomic approaches to tailor treatments for patients, and the growing trend of holistic treatments combining physical, psychological, and alternative therapies. However, the market faces significant limitations, including underdiagnosis, social stigma, and limited knowledge among general practitioners, which can hinder patient referrals and access to treatment. Price sensitivity and lack of insurance coverage for certain therapies can also pose challenges to market penetration. Innovation and research areas poised for growth include the development of non-opioid analgesics, advancements in laser therapies, and digital health tools such as apps for patient management and education. These innovations can enhance patient adherence and treatment outcomes. The nature of the vulvodynia treatment market is dynamic, driven by evolving patient demands for less invasive and more effective treatments. Companies looking to enter or expand in this market should focus on partnerships with healthcare providers, investing in patient education programs, and fostering community support networks to mitigate social barriers and improve treatment accessibility.

KEY MARKET STATISTICS
Base Year [2023] USD 55.53 billion
Estimated Year [2024] USD 60.82 billion
Forecast Year [2030] USD 105.67 billion
CAGR (%) 9.62%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vulvodynia Treatment Market

The Vulvodynia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing knowledge of vulvodynia diagnostics among clinicians, particularly gynecologists
    • Developments in healthcare facilities and diagnostic services
    • Increase in the number of research and development activities
  • Market Restraints
    • Unidentified causes and limited diagnosis options
  • Market Opportunities
    • Doctors offering self-care and treatments for vulvodynia
    • Prolonged availability of off-label drugs
  • Market Challenges
    • Limited familiarity of health care providers with vulvodynia

Porter's Five Forces: A Strategic Tool for Navigating the Vulvodynia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vulvodynia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vulvodynia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vulvodynia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vulvodynia Treatment Market

A detailed market share analysis in the Vulvodynia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vulvodynia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vulvodynia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vulvodynia Treatment Market

A strategic analysis of the Vulvodynia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vulvodynia Treatment Market, highlighting leading vendors and their innovative profiles. These include Amneal Pharmaceuticals, Inc., Cipla Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Inc., GTO Pharmaceutical, LLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Taro Pharmaceutical Industries Ltd., Upsher-Smith Laboratories, LLC, VuVatech LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vulvodynia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Biofeedback & Physical Therapy, Intralesional Injections, Oral Treatment, Surgical Treatment, and Topical Treatments.
  • Based on Indication, market is studied across Generalized Vulvodynia and Localized Vulvodynia.
  • Based on Providers, market is studied across Hospitals & Care Providers, Pharmaceutical & Biotechnology Companies, and Research & Development Centres.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing knowledge of vulvodynia diagnostics among clinicians, particularly gynecologists
      • 5.1.1.2. Developments in healthcare facilities and diagnostic services
      • 5.1.1.3. Increase in the number of research and development activities
    • 5.1.2. Restraints
      • 5.1.2.1. Unidentified causes and limited diagnosis options
    • 5.1.3. Opportunities
      • 5.1.3.1. Doctors offering self-care and treatments for vulvodynia
      • 5.1.3.2. Prolonged availability of off-label drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Limited familiarity of health care providers with vulvodynia
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vulvodynia Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Biofeedback & Physical Therapy
  • 6.3. Intralesional Injections
  • 6.4. Oral Treatment
  • 6.5. Surgical Treatment
  • 6.6. Topical Treatments

7. Vulvodynia Treatment Market, by Indication

  • 7.1. Introduction
  • 7.2. Generalized Vulvodynia
  • 7.3. Localized Vulvodynia

8. Vulvodynia Treatment Market, by Providers

  • 8.1. Introduction
  • 8.2. Hospitals & Care Providers
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Research & Development Centres

9. Americas Vulvodynia Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Vulvodynia Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Vulvodynia Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amneal Pharmaceuticals, Inc.
  • 2. Cipla Ltd.
  • 3. Eli Lilly and Company
  • 4. GlaxoSmithKline PLC
  • 5. Glenmark Pharmaceuticals Inc.
  • 6. GTO Pharmaceutical, LLC
  • 7. Hikma Pharmaceuticals PLC
  • 8. Johnson & Johnson Services, Inc.
  • 9. Novartis AG
  • 10. Pfizer Inc.
  • 11. Taro Pharmaceutical Industries Ltd.
  • 12. Upsher-Smith Laboratories, LLC
  • 13. VuVatech LLC
  • 14. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. VULVODYNIA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. VULVODYNIA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VULVODYNIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VULVODYNIA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY BIOFEEDBACK & PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INTRALESIONAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY ORAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY GENERALIZED VULVODYNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY LOCALIZED VULVODYNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VULVODYNIA TREATMENT MARKET SIZE, BY RESEARCH & DEVELOPMENT CENTRES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES VULVODYNIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM VULVODYNIA TREATMENT MARKET SIZE, BY PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 147. VULVODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. VULVODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023